Clinical Trials Logo

Chronic Lymphocytic B-Leukemia clinical trials

View clinical trials related to Chronic Lymphocytic B-Leukemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00058786 Completed - Clinical trials for Chronic Lymphocytic B-Leukemia

Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells

CLIMAT
Start date: December 2002
Phase: Phase 1
Study type: Interventional

This is a research study to determine the safety and dosage of special cells that may make the patients own immune system fight the cancer. To do this, we will put a special gene into cancer cells that have been taken from the patient. This will be done in the laboratory. This gene will make the cells produce interleukin 2 (IL-2), which is a natural substance that may help the immune system kill cancer cells. Additionally, we will stimulate the cancer cells with another natural protein called CD40 ligand (CD40L), which preclinical human and animal studies suggest will help IL-2 perform better. Some of these cells will then be put back into the body. The cells are grown with normal embryonic fibroblasts. Studies of cancers in animals and in cancer cells that are grown in laboratories suggest that combining substances like IL-2 and CD40L helps the body kill cancer cells. The purpose of this study is to learn the side effects and the safest effective dose of these special cells on the disease